HLA-E and B-cell chronic lymphocytic leukemia: Additionally, lenalidomide treatment alters CLL cells by increasing CD20 expression, decreasing MHC-I, increasing HLA-E, and decreasing the rituximab concentration needed to activate NKs [113,246,247].